CellSource Co., Ltd. (JP:4880) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CellSource Co., Ltd. will commence consolidated financial reporting starting from the fiscal year ending October 31, 2025, following the establishment of its subsidiary, Hybrid Medical Co., Ltd. The company has released its financial forecasts, projecting net sales of 4,501 million yen and a profit of 255 million yen for the upcoming fiscal year. These forecasts include the anticipated performance of Hybrid Medical.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.